scholarly journals A Nomogram for Individual Prediction of Poor Prognosis After Radical Surgery in Patients with Primary Pancreatic Duct Adenocarcinoma

2020 ◽  
Vol 26 ◽  
Author(s):  
Shuyu Zhai ◽  
Zhen Huo ◽  
Xiayang Ying ◽  
Jiabin Jin ◽  
Yue Wang ◽  
...  
Keyword(s):  
Pancreatic Duct ◽  
Poor Prognosis ◽  
Radical Surgery ◽  
Pancreatic Duct Adenocarcinoma

scholarly journals MicroRNA-140 regulates cell growth and invasion in pancreatic duct adenocarcinoma by targeting iASPP

2016 ◽  
Vol 48 (2) ◽  
pp. 174-181 ◽  
Author(s):  
Shuai Liang ◽  
Xuejun Gong ◽  
Gewen Zhang ◽  
Gengwen Huang ◽  
Yebin Lu ◽  
...  
Keyword(s):  
Cell Growth ◽  
Pancreatic Duct ◽  
Pancreatic Duct Adenocarcinoma

scholarly journals Durable response to olaparib in pancreatic duct adenocarcinoma with deleterious ARID1A mutation

2019 ◽  
Vol 132 (24) ◽  
pp. 3012-3014
Author(s):  
Xue-Song Zhao ◽  
Jing Zhou ◽  
Lei Dong ◽  
Hui Zhang ◽  
Ying-Jiang Ye
Keyword(s):  
Pancreatic Duct ◽  
Durable Response ◽  
Pancreatic Duct Adenocarcinoma

scholarly journals Inactivation of Rab23 inhibits the invasion and motility of pancreatic duct adenocarcinoma

2015 ◽  
Vol 14 (1) ◽  
pp. 2707-2715 ◽  
Author(s):  
Z.Z. Cai ◽  
L.B. Xu ◽  
J.L. Cai ◽  
J.S. Wang ◽  
B. Zhou ◽  
...  
Keyword(s):  
Pancreatic Duct ◽  
Pancreatic Duct Adenocarcinoma

scholarly journals A Competing-Risks Nomogram in Patients with Metastatic Pancreatic Duct Adenocarcinoma

2019 ◽  
Vol 25 ◽  
pp. 3683-3691
Author(s):  
Yanwu Lu ◽  
Yiqun Zhou ◽  
Yi Cao ◽  
Zheng Shi ◽  
Qinghai Meng
Keyword(s):  
Pancreatic Duct ◽  
Competing Risks ◽  
Pancreatic Duct Adenocarcinoma

scholarly journals Laparoscopic Pancreaticoduodenectomy Versus Conventional Open Approach for Patients With Pancreatic Duct Adenocarcinoma: An Up-to-Date Systematic Review and Meta-Analysis

2021 ◽  
Vol 11 ◽  
Author(s):  
Qingbo Feng ◽  
Wenwei Liao ◽  
Zechang Xin ◽  
Hongyu Jin ◽  
Jinpeng Du ◽  
...  
Keyword(s):  
Systematic Review ◽  
Overall Survival ◽  
Lymph Node ◽  
Blood Loss ◽  
Survival Time ◽  
Pancreatic Duct ◽  
Meta Analysis ◽  
R0 Resection ◽  
Node Dissection ◽  
Pancreatic Duct Adenocarcinoma

BackgroundTo compare perioperative and oncological outcomes of pancreatic duct adenocarcinoma (PDAC) after laparoscopic versus open pancreaticoduodenectomy (LPD vs. OPD), we performed a meta-analysis of currently available propensity score matching studies and large-scale retrospective cohorts to compare the safety and overall effect of LPD to OPD for patients with PDAC.MethodsA meta-analysis was registered at PROSPERO and the registration number is CRD42021250395. PubMed, Web of Science, EMBASE, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov databases were searched based on a defined search strategy to identify eligible studies before March 2021. Data on operative times, blood loss, 30-day mortality, reoperation, length of hospital stay (LOS), overall morbidity, Clavien–Dindo ≥3 complications, postoperative pancreatic fistula (POPF), blood transfusion, delayed gastric emptying (DGE), postpancreatectomy hemorrhage (PPH), and oncologic outcomes (R0 resection, lymph node dissection, overall survival, and long-term survival) were subjected to meta-analysis.ResultsOverall, we identified 10 retrospective studies enrolling a total of 11,535 patients (1,514 and 10,021 patients underwent LPD and OPD, respectively). The present meta-analysis showed that there were no significant differences in overall survival time, 1-year survival, 2-year survival, 30-day mortality, Clavien-Dindo ≥3 complications, POPF, DGE, PPH, and lymph node dissection between the LPD and OPD groups. Nevertheless, compared with the OPD group, LPD resulted in significantly higher rate of R0 resection (OR: 1.22; 95% CI 1.06–1.40; p = 0.005), longer operative time (WMD: 60.01 min; 95% CI 23.23–96.79; p = 0.001), lower Clavien–Dindo grade ≥III rate (p = 0.02), less blood loss (WMD: −96.49 ml; 95% CI −165.14 to −27.83; p = 0.006), lower overall morbidity rate (OR: 0.65; 95% CI 0.50 to 0.85; p = 0.002), shorter LOS (MD = −2.73; 95% CI −4.44 to −1.03; p = 0.002), higher 4-year survival time (p = 0.04), 5-year survival time (p = 0.001), and earlier time to starting adjuvant chemotherapy after surgery (OR: −10.86; 95% CI −19.42 to −2.30; p = 0.01).ConclusionsLPD is a safe and feasible alternative to OPD for patients with PDAC, and compared with OPD, LPD seemed to provide a similar OS.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/#recordDetails.

Significant up-regulation of vasodilator-stimulated phosphoprotein in human pancreatic duct adenocarcinoma.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e15674-e15674
Author(s):  
Yifan Tu ◽  
Selvaraj Muthusamy ◽  
Ningling Kang ◽  
Nishant Poddar ◽  
Jinping Lai
Keyword(s):  
Pancreatic Duct ◽  
Pancreatic Duct Adenocarcinoma

Early pancreatic duct adenocarcinoma

1988 ◽  
Vol 19 (2) ◽  
pp. 242-244 ◽  
Author(s):  
Kazuhiro Mizumoto ◽  
Takehiko Inagaki ◽  
Masaki Koizumi ◽  
Masato Uemura ◽  
Masaaki Ogawa ◽  
...  
Keyword(s):  
Pancreatic Duct ◽  
Pancreatic Duct Adenocarcinoma
Sign in / Sign up

Export Citation Format

Share Document